- Home
- MLTX vs AOD Comparison
MLTX vs AOD Comparison
Compare MLTX & AOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MLTX | AOD |
|---|---|---|
| Founded | 2021 | 2006 |
| Country | Switzerland | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 979.8M | 1.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MLTX | AOD |
|---|---|---|
| Price | $16.15 | $9.97 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $22.22 | N/A |
| AVG Volume (30 Days) | ★ 3.6M | 423.5K |
| Earning Date | 02-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.95% |
| EPS Growth | N/A | ★ 213.63 |
| EPS | N/A | ★ 1.93 |
| Revenue | N/A | ★ $72,962,082.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.44 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.95 | $6.99 |
| 52 Week High | $62.75 | $9.14 |
Technical Indicators
Market Signals| Indicator | MLTX | AOD |
|---|---|---|
| Relative Strength Index (RSI) | 55.11 | 53.55 |
| Support Level | $15.70 | $9.92 |
| Resistance Level | $16.86 | $10.11 |
| Average True Range (ATR) | 1.30 | 0.12 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 65.06 | 43.43 |
Price Performance
Historical ComparisonAbout MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
About AOD abrdn Total Dynamic Dividend Fund of Beneficial Interest
Aberdeen Total Dynamic Dividend Fund is a diversified, closed-end management investment company. Its investment objective is to seek high current dividend income. The company also focuses on the long-term growth of capital as a secondary investment objective. The fund invests in foreign securities, including direct investments in securities of foreign issuers and investments in depositary receipts that represent indirect interests in securities of foreign issuers. Its portfolio consists of securities from Information Technology, Financial, Healthcare, and Industrials among other sectors.